These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 25146834)

  • 1. Comment to the paper: The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma : Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski, Ania Marszalek.
    Blaskiewicz R
    Childs Nerv Syst; 2014 Dec; 30(12):2067-8. PubMed ID: 25146834
    [No Abstract]   [Full Text] [Related]  

  • 2. Main editor's comment to the paper: the response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski, Ania Marszalek.
    Di Rocco C
    Childs Nerv Syst; 2014 Dec; 30(12):2063. PubMed ID: 25096071
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment to the paper "The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brain stem glioma" by Burzynski et al.
    Wong TT
    Childs Nerv Syst; 2014 Dec; 30(12):2069-70. PubMed ID: 25142686
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary: The response and survival of children with recurrent diffuse intrisic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma, by Burzynski G, et al.
    Massimino M; Clerici CA
    Childs Nerv Syst; 2014 Dec; 30(12):2065-6. PubMed ID: 25079885
    [No Abstract]   [Full Text] [Related]  

  • 5. Commentary on: "The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma." By Burzynski et al.
    Perilongo G
    Childs Nerv Syst; 2014 Dec; 30(12):2071-2. PubMed ID: 25330863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.
    Burzynski SR; Janicki TJ; Burzynski GS; Marszalek A
    Childs Nerv Syst; 2014 Dec; 30(12):2051-61. PubMed ID: 24718705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.
    Burzynski SR; Lewy RI; Weaver R; Janicki T; Jurida G; Khan M; Larisma CB; Paszkowiak J; Szymkowski B
    Integr Cancer Ther; 2004 Sep; 3(3):257-61. PubMed ID: 15312271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.
    Burzynski SR; Lewy RI; Weaver RA; Axler ML; Janicki TJ; Jurida GF; Paszkowiak JK; Szymkowski BG; Khan MI; Bestak M
    Drugs R D; 2003; 4(2):91-101. PubMed ID: 12718563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.
    Burzynski SR; Janicki TJ; Weaver RA; Burzynski B
    Integr Cancer Ther; 2006 Mar; 5(1):40-7. PubMed ID: 16484713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report.
    Burzynski SR; Weaver RA; Lewy RI; Janicki TJ; Jurida GF; Szymkowski BG; Khan MI; Bestak M
    Drugs R D; 2004; 5(6):315-26. PubMed ID: 15563234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quick response of advanced cancer to chemoradiation therapy with antineoplastons.
    Tsuda H; Sata M; Kumabe T; Hara H; Eriguchi N; Sugita Y; Nagamatsu H
    Oncol Rep; 1998; 5(3):597-600. PubMed ID: 9538158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma.
    Buckner JC; Malkin MG; Reed E; Cascino TL; Reid JM; Ames MM; Tong WP; Lim S; Figg WD
    Mayo Clin Proc; 1999 Feb; 74(2):137-45. PubMed ID: 10069350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing social conflict in complementary and alternative medicine research: the case of antineoplastons.
    Hammer MR; Jonas WB
    Integr Cancer Ther; 2004 Mar; 3(1):59-65. PubMed ID: 15035877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of antineoplastons A10 and AS2-1.
    Burzynski SR
    Mayo Clin Proc; 1999 Jun; 74(6):641-2. PubMed ID: 10377942
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma.
    Tsuda H; Iemura A; Sata M; Uchida M; Yamana K; Hara H
    Kurume Med J; 1996; 43(2):137-47. PubMed ID: 8755117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete response and long-term survival (>20 years) of a child with tectal glioma: a case report.
    Burzynski SR; Burzynski GS; Janicki TJ; Marszalek A
    Pediatr Neurosurg; 2015; 50(2):99-103. PubMed ID: 25926271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stanislaw R. Burzynski, MD, PhD: novel cancer research and the fight to prove its worth.
    Burzynski SR
    Altern Ther Health Med; 2012; 18(3):54-61. PubMed ID: 22875562
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1.
    Burzynski SR; Weaver RA; Janicki T; Szymkowski B; Jurida G; Khan M; Dolgopolov V
    Integr Cancer Ther; 2005 Jun; 4(2):168-77. PubMed ID: 15911929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of Antineoplaston, a new antitumor agent on malignant brain tumors.
    Sugita Y; Tsuda H; Maruiwa H; Hirohata M; Shigemori M; Hara H
    Kurume Med J; 1995; 42(3):133-40. PubMed ID: 7474850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients.
    Tsuda H; Hara H; Eriguchi N; Nishida H; Yoshida H; Kumabe T; Sugita Y
    Kurume Med J; 1995; 42(4):241-9. PubMed ID: 8667595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.